Related Experiment Video
Updated: Jun 26, 2026

An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus
Published on: August 25, 2017
Treatment for Kaposi sarcoma herpesvirus: great challenges with promising accomplishments
1Division of Infectious Diseases, Department of Pediatrics, Johns Hopkins Hospital, Baltimore, MD, 21287-4933, USA. boger@jhmi.edu
Abstract:
Kaposi sarcoma-associated herpesvirus (KSHV) is associated with three distinct malignancies: Kaposi sarcoma (KS), primary effusion lymphoma, and multicentric Castleman disease. Treatment modalities for KSHV have largely been developed based on understanding its molecular pathogenesis. The KSHV genome has been fully sequenced and contains numerous genes with homology to human regulatory genes that are potentially important in KS development. Therapeutic strategies have been developed to target signaling pathways that are activated by KSHV. This review describes multiple classes of pharmacological compounds that have been studied in patients with KS, including antivirals, chemotherapeutics, and novel agents related to KSHV pathogenesis.
Related Concept Videos
Cryptococcal Meningitis
Treatment Resistent Cancers
Retrovirus Life Cycles
Treatment Resistant Cancers
Genital Herpes
Herpes

